Abbas Motazedi, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1962572644
Payments from drug & device makers
Across 557 payments — averaging $56.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Boehringer Ingelheim$2K
- Lilly USA, LLC$2K
- Amneal Pharmaceuticals LLC$1K
- Bayer$952
- Amgen$809
- plus $5K from 33 others
What the payments were for
- Consulting fees$1751%
- Speaking & faculty fees$18,35059%
- Travel & lodging$1160%
- Food & beverage$12,56240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $19,797 |
| Boehringer Ingelheim | 84 | $2,079 |
| Lilly USA, LLC | 84 | $1,560 |
| Amneal Pharmaceuticals LLC | 67 | $1,288 |
| Bayer | 39 | $952 |
| Amgen(2 entities) | 25 | $809 |
| Sanofi-aventis U.S. LLC | 39 | $724 |
| Insulet Corporation | 20 | $680 |
| AbbVie | 28 | $512 |
| Abbott | 18 | $397 |
| Dexcom, Inc. | 15 | $362 |
| Tandem Diabetes Care, Inc. | 8 | $315 |
| Mannkind Corporation | 10 | $194 |
| Merck | 10 | $192 |
| Novo Nordisk | 7 | $138 |
| Xeris Pharmaceuticals, Inc. | 6 | $128 |
| Esperion Therapeutics, Inc. | 5 | $124 |
| BETA Bionics, Inc. | 5 | $112 |
| Corcept Therapeutics | 4 | $92 |
| Medtronic | 3 | $86 |
| Acella Pharmaceuticals, LLC | 4 | $84 |
| Novartis | 4 | $75 |
| Johnson & Johnson | 4 | $62 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Sanofi Pasteur Inc. | 2 | $49 |
| Cequr Corporation | 1 | $39 |
| Sequel Med Tech, LLC | 1 | $29 |
| GSK | 1 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Embecta Corp. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Lifescan, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Valeritas, Inc. | 1 | $20 |
| Intuity Medical Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,203 in reported general payments places this provider in the 80th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 331 | $627,614 |
| TrulicityDulaglutide | 258 | $434,599 |
| JardianceEmpagliflozin | 248 | $305,375 |
| FarxigaDapagliflozin Propanediol | 78 | $110,898 |
| SynjardyEmpagliflozin/Metformin Hcl | 60 | $94,883 |
| OzempicSemaglutide | 42 | $64,866 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $61,363 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $45,089 |
| KerendiaFinerenone | 32 | $37,988 |
| JanuviaSitagliptin Phosphate | 32 | $32,461 |
| Cinacalcet Hcl | 43 | $28,229 |
| ProliaDenosumab | 16 | $27,989 |
| Humalog Kwikpen U-100Insulin Lispro | 95 | $26,692 |
| RybelsusSemaglutide | 11 | $25,702 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 57 | $24,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,560 | $1,069,125615 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta, Jentadueto | $2,079 | $452,181361 claims |
| AstraZenecaFarxiga | $19,797 | $110,89878 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $138 | $101,80481 claims |
| MerckJanumet, Januvia | $192 | $77,55067 claims |
| BayerKerendia | $952 | $37,98832 claims |
| AmgenProlia | $809 | $27,98916 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $1,288 | $10,720510 claims |
| AbbVieSynthroid | $512 | $8,26980 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Henry BurchWashington$25.2M
- Sabyasachi SenWashington$1.4M
- Adline GhaziWashington$1.2M
- Kenneth BurmanWashington$219K
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Michelle MageeWashington$61K
- Julia PinedaWashington$29K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.